209 related articles for article (PubMed ID: 38052038)
1. Phase 1b trial of tagraxofusp in combination with azacitidine with or without venetoclax in acute myeloid leukemia.
Lane AA; Garcia JS; Raulston EG; Garzon JL; Galinsky I; Baxter EW; Leonard R; DeAngelo DJ; Luskin MR; Reilly CR; Stahl M; Stone RM; Vedula RS; Wadleigh MM; Winer ES; Mughal T; Brooks C; Gupta IV; Stevenson KE; Neuberg DS; Ren S; Keating J; Konopleva M; Stein A; Pemmaraju N
Blood Adv; 2024 Feb; 8(3):591-602. PubMed ID: 38052038
[TBL] [Abstract][Full Text] [Related]
2. [Short-term efficacy of venetoclax combined with azacitidine in acute myeloid leukemia: a single-institution experience].
Yu WJ; Jia JS; Wang J; Tang FF; Gong LZ; Liu XH; Zhu XL; Zhao XS; Huang XJ; Jiang H
Zhonghua Xue Ye Xue Za Zhi; 2022 Feb; 43(2):134-140. PubMed ID: 35381674
[No Abstract] [Full Text] [Related]
3. Clinical experience with the BCL2-inhibitor venetoclax in combination therapy for relapsed and refractory acute myeloid leukemia and related myeloid malignancies.
DiNardo CD; Rausch CR; Benton C; Kadia T; Jain N; Pemmaraju N; Daver N; Covert W; Marx KR; Mace M; Jabbour E; Cortes J; Garcia-Manero G; Ravandi F; Bhalla KN; Kantarjian H; Konopleva M
Am J Hematol; 2018 Mar; 93(3):401-407. PubMed ID: 29218851
[TBL] [Abstract][Full Text] [Related]
4. Single-center pediatric experience with venetoclax and azacitidine as treatment for myelodysplastic syndrome and acute myeloid leukemia.
Winters AC; Maloney KW; Treece AL; Gore L; Franklin AK
Pediatr Blood Cancer; 2020 Oct; 67(10):e28398. PubMed ID: 32735397
[TBL] [Abstract][Full Text] [Related]
5. Efficacy of Venetoclax and Azacitidine in Acute Myeloid Leukemia Compared to Azacitidine Monotherapy: Real-World Experience.
Baba Y; Hida N; Sambe T; Abe M; Kabasawa N; Sakai H; Yoshimura K; Fukuda T
Anticancer Res; 2024 May; 44(5):2003-2007. PubMed ID: 38677735
[TBL] [Abstract][Full Text] [Related]
6. Allogeneic hematopoietic cell transplantation for acute myeloid leukemia in first complete remission after 5-azacitidine and venetoclax: a multicenter retrospective study.
Pasvolsky O; Shimony S; Ram R; Shimoni A; Shargian L; Avni B; Wolach O; Shochat T; Yerushalmi R; Amit O; Raanani P; Yeshurun M
Ann Hematol; 2022 Feb; 101(2):379-387. PubMed ID: 34628534
[TBL] [Abstract][Full Text] [Related]
7. Safety and preliminary efficacy of venetoclax with decitabine or azacitidine in elderly patients with previously untreated acute myeloid leukaemia: a non-randomised, open-label, phase 1b study.
DiNardo CD; Pratz KW; Letai A; Jonas BA; Wei AH; Thirman M; Arellano M; Frattini MG; Kantarjian H; Popovic R; Chyla B; Xu T; Dunbar M; Agarwal SK; Humerickhouse R; Mabry M; Potluri J; Konopleva M; Pollyea DA
Lancet Oncol; 2018 Feb; 19(2):216-228. PubMed ID: 29339097
[TBL] [Abstract][Full Text] [Related]
8. Prophylactic maintenance with venetoclax/azacitidine after reduced-intensity conditioning allogeneic transplant for high-risk MDS and AML.
Garcia JS; Kim HT; Murdock HM; Ansuinelli M; Brock J; Cutler CS; Gooptu M; Ho VT; Koreth J; Nikiforow S; Romee R; Shapiro R; DeAngelo DJ; Stone RM; Bat-Erdene D; Ryan J; Contreras ME; Fell G; Letai A; Ritz J; Lindsley RC; Soiffer RJ; Antin JH
Blood Adv; 2024 Feb; 8(4):978-990. PubMed ID: 38197938
[TBL] [Abstract][Full Text] [Related]
9. The efficacy and adverse events of venetoclax in combination with hypomethylating agents treatment for patients with acute myeloid leukemia and myelodysplastic syndrome: a systematic review and meta-analysis.
Liu B; Guo Y; Deng L; Qiao Y; Jian J
Hematology; 2020 Dec; 25(1):414-423. PubMed ID: 33191860
[TBL] [Abstract][Full Text] [Related]
10. Efficacy and safety of venetoclax-based combination therapy for previously untreated acute myeloid leukemia: a meta-analysis.
He H; Wen X; Zheng H
Hematology; 2024 Dec; 29(1):2343604. PubMed ID: 38703055
[TBL] [Abstract][Full Text] [Related]
11. Azacitidine-venetoclax versus azacitidine salvage treatment for primary induction failure or first relapsed acute myeloid leukaemia patients.
Petit C; Saillard C; Mohty B; Hicheri Y; Villetard F; Maisano V; Charbonnier A; Rey J; D'Incan E; Rouzaud C; Gelsi-Boyer V; Murati A; Lhoumeau AC; Ittel A; Mozziconacci MJ; Alary AS; Hospital MA; Vey N; Garciaz S
Eur J Haematol; 2024 Apr; 112(4):530-537. PubMed ID: 38031389
[TBL] [Abstract][Full Text] [Related]
12. Venetoclax combined with decitabine or azacitidine in treatment-naive, elderly patients with acute myeloid leukemia.
DiNardo CD; Pratz K; Pullarkat V; Jonas BA; Arellano M; Becker PS; Frankfurt O; Konopleva M; Wei AH; Kantarjian HM; Xu T; Hong WJ; Chyla B; Potluri J; Pollyea DA; Letai A
Blood; 2019 Jan; 133(1):7-17. PubMed ID: 30361262
[TBL] [Abstract][Full Text] [Related]
13. [The Efficacy and Safety of Venetoclax Combined with Azacitidine in the Treatment of Adult Patients with Acute Myeloid Leukemia Who Are Unfit for Intensive Chemotherapy].
Wang KY; Fan BR; Zhang QW; Han MR; Ge XY
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2024 Apr; 32(2):342-346. PubMed ID: 38660834
[TBL] [Abstract][Full Text] [Related]
14. Efficacy and safety of enasidenib and azacitidine combination in patients with IDH2 mutated acute myeloid leukemia and not eligible for intensive chemotherapy.
Venugopal S; Takahashi K; Daver N; Maiti A; Borthakur G; Loghavi S; Short NJ; Ohanian M; Masarova L; Issa G; Wang X; Carlos BR; Yilmaz M; Kadia T; Andreeff M; Ravandi F; Konopleva M; Kantarjian HM; DiNardo CD
Blood Cancer J; 2022 Jan; 12(1):10. PubMed ID: 35078972
[TBL] [Abstract][Full Text] [Related]
15. A phase 1/2 study of azacitidine, venetoclax and pevonedistat in newly diagnosed secondary AML and in MDS or CMML after failure of hypomethylating agents.
Short NJ; Muftuoglu M; Ong F; Nasr L; Macaron W; Montalban-Bravo G; Alvarado Y; Basyal M; Daver N; Dinardo CD; Borthakur G; Jain N; Ohanian M; Jabbour E; Issa GC; Qiao W; Huang X; Kanagal-Shamanna R; Patel KP; Bose P; Ravandi F; Delumpa R; Abramova R; Garcia-Manero G; Andreeff M; Cortes J; Kantarjian H
J Hematol Oncol; 2023 Jul; 16(1):73. PubMed ID: 37422688
[TBL] [Abstract][Full Text] [Related]
16. A Real-life Turkish Experience of Venetoclax Treatment in High-risk Myelodysplastic Syndrome and Acute Myeloid Leukemia.
Gemici A; Ozkalemkas F; Dogu MH; Tekinalp A; Alacacioglu I; Guney T; Ince I; Geduk A; Cagliyan GA; Maral S; Serin I; Gunduz E; Karakus V; Bekoz HS; Eren R; Pinar IE; Gunes AK; Sargın FD; Sevindik OG
Clin Lymphoma Myeloma Leuk; 2021 Aug; 21(8):e686-e692. PubMed ID: 34059487
[TBL] [Abstract][Full Text] [Related]
17. Azacitidine plus venetoclax in patients with high-risk myelodysplastic syndromes or chronic myelomonocytic leukaemia: phase 1 results of a single-centre, dose-escalation, dose-expansion, phase 1-2 study.
Bazinet A; Darbaniyan F; Jabbour E; Montalban-Bravo G; Ohanian M; Chien K; Kadia T; Takahashi K; Masarova L; Short N; Alvarado Y; Yilmaz M; Ravandi F; Andreeff M; Kanagal-Shamanna R; Ganan-Gomez I; Colla S; Qiao W; Huang X; McCue D; Mirabella B; Kantarjian H; Garcia-Manero G
Lancet Haematol; 2022 Oct; 9(10):e756-e765. PubMed ID: 36063832
[TBL] [Abstract][Full Text] [Related]
18. Clinical experience with venetoclax in patients with newly diagnosed, relapsed, or refractory acute myeloid leukemia.
Fleischmann M; Scholl S; Frietsch JJ; Hilgendorf I; Schrenk K; Hammersen J; Prims F; Thiede C; Hochhaus A; Schnetzke U
J Cancer Res Clin Oncol; 2022 Nov; 148(11):3191-3202. PubMed ID: 35099591
[TBL] [Abstract][Full Text] [Related]
19. Single-institution experience of venetoclax combined with azacitidine in newly diagnosed acute myeloid leukemia patients.
Yu H; Wang C; Lei Y; Li L; Wang H; Wang G; Xing L; Guan J; Song J; Wu Y; Liu H; Qu W; Wang X; Shao Z; Fu R
Int Immunopharmacol; 2024 Jan; 127():111232. PubMed ID: 38091830
[TBL] [Abstract][Full Text] [Related]
20. Multi-gene measurable residual disease assessed by digital polymerase chain reaction has clinical and biological utility in acute myeloid leukemia patients receiving venetoclax/azacitidine.
Winters AC; Minhajuddin M; Stevens BM; Major A; Bosma G; Abbott D; Miltgen N; Yuan J; Treece AL; Siegele BJ; Ewalt MD; Gutman JA; Jordan CT; Pollyea DA
Haematologica; 2024 Jun; 109(6):1766-1778. PubMed ID: 38105738
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
